The DEEP project has received research funding from the European Union under the 7th Framework Programme
A big project milestone has been reached as the last few patients have been randomized. Thanks to the last achievements and efforts made by the PIs to recruit patients, the DEEP-2 Study has finally completed the enrollment.
The last patients were included […]
Another step forward has been made toward the enrollment of new patients, which is allowed by the end of October 2015.
Principal Investigators (PIs) are still working to continue the enrollment of patients within the DEEP-2 study and to date a total of 117 patients have been […]
On January 31st, 2013 recruitment started in the DEEP-1 study (multi-centre, oral single dose experimental and modelling study to evaluate the pharmacokinetics of deferiprone in patients aged from 1 month to less than 6 years of age affected by transfusion-dependent haemoglobinopathies) and the first patient […]
On February 15th 2013 recruitment started for the DEEP-3 study (multi-centre, long-term observational safety study to evaluate the nature and incidence of adverse effects of deferiprone treatment in patients with beta-thalassaemia major aged from 1 month to less than 18 years). The first patient […]
